Update: PPMI iPSC Lines

Mon, Jun 19, 2017

Cell lines derived from PPMI participants, PBMCs become available on a rolling basis as they are reprogrammed; some lines are available now. For more information, please email resources@michaeljfox.org. Information about additional tools for PD research, including animal models, antibodies, and assays, can be found on the Michael J. Fox Foundation website.

The Parkinson’s Progression Markers Initiative (PPMI) has expanded to include the generation of induced pluripotent stem cell (iPSC) lines from reprogrammed peripheral mononuclear blood cells (PBMCs) collected from PPMI participants. In January of 2017, PPMI study leadership challenged participating sites to complete 135 blood collections by the end of the year.

Staff at eight PPMI sties have enthusiastically accepted the challenge. In particular, study leadership would like to recognize the Institute for Neurodegenerative Disorders, Boston University, and University of California, San Diego for leading the way with the highest blood collection recruitment numbers. We are now closing in our recruitment goal; to date, PPMI sites have complete 92 blood collections. An additional 13 study participants are scheduled to give blood for iPSC lines, putting PPMI within 30 collections of our overall recruitment goal of 135 collections.

Cell lines are derived from participants who have idiopathic Parkinson’s disease (PD), healthy volunteers, participants with clinical risk factors for PD, and participants with and without PD who have genetic risk factors for PD (GBA1, LRRK2, and SNCA mutations). The Michael J. Fox Foundation (MJFF) hopes that iPSC lines and PPMI clinical data can be leveraged together for biomarker research, drug screening, and disease modeling.